According to clinicaltrials.gov under the U.S. National Institutes of Health, the EU Clinical Trials Register, and the International Clinical Trials Registry Platform under the World Health Organization (WHO), the following trials are currently or soon to be recruiting (as of 24 November 2024).
Read more about these and other clinical trials at:
HAELO: a Phase 3 Study to Evaluate NTLA-2002 in Participants with Hereditary Angioedema (HAE)
United States
https://clinicaltrials.gov/study/NCT06634420
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Belgium, Bulgaria, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Turkey, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05392114
A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People (SPEAKUP)
No sites confirmed
https://clinicaltrials.gov/study/NCT06587464
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Poland
https://clinicaltrials.gov/study/NCT05147181
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, Sweden
https://www.clinicaltrials.gov/study/NCT01397864
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
United Kingdom
https://clinicaltrials.gov/study/NCT05469789
A Survey of Lanadelumab in Participants With Hereditary Angioedema
Japan
https://clinicaltrials.gov/study/NCT05397431
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Japan
https://clinicaltrials.gov/study/NCT05509569
A Study of STAR-0215 in Participants With Hereditary Angioedema
Bulgaria, Canada, Czechia, Germany, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05695248
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
United States, Canada
https://www.clinicaltrials.gov/study/NCT06007677
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Australia, Austria, Bulgaria, France, Germany, Greece, Israel, Japan, Netherlands, New Zealand, Spain, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05511922
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
Israel, United States
https://clinicaltrials.gov/study/NCT05819775
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Australia, Austria, Bulgaria, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Slovakia, South Africa, Spain, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05505916
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Poland, Spain, United States
https://clinicaltrials.gov/study/NCT05396105
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema (RAPIDe-3)
United States, Puerto Rico
https://www.clinicaltrials.gov/study/NCT06343779
Status of Dental Care Practices in Patients With Hereditary Angioedema
France
https://clinicaltrials.gov/study/NCT05776784
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C-1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
United States, Armenia, Bulgaria, Mexico, Peru, Romania, Serbia, Ukraine
https://www.clinicaltrials.gov/study/NCT06361537
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
Australia
https://clinicaltrials.gov/study/NCT05691361
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
France, New Zealand, United Kingdom
https://www.clinicaltrials.gov/study/NCT06262399
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr) in Persons With HAE in China
China
https://clinicaltrials.gov/study/NCT06346899
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with HAE Type I or II (KONFIDENT-KID)
United States
https://clinicaltrials.gov/study/NCT06467084
Institutional Registry of Rare Diseases
Argentina
https://www.clinicaltrials.gov/study/NCT06573723
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE (CHAPTER-3)
No location data
https://www.clinicaltrials.gov/study/NCT06669754
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with HAE (CHAPTER-4)
No location data
https://www.clinicaltrials.gov/study/NCT06679881
Angioedema Biomarker Research Study
No location data
https://www.clinicaltrials.gov/study/NCT06210698